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We evaluated whether regular mammographie screening of 
women aged 65 years or older affected breast cancer mortality. 
In Nijmegen, a population-based screening program for breast 
cancer was started in 1975, with biennial mammography for 
women aged 35-64 years. Since 1977, elderly women have also 
been participating. For the present case-control study, women 
were selected who were over 64 years of age at the most recent 
invitation. Eighty-two of them had died from breast cancer. For 
these cases, 410 age-matched population controls were se­
lected. The ratio of breast cancer mortality rates of the women 
who had participated regularly (i.e., in the 2 most recent screen­
ing rounds prior to diagnosis) vs. the women who had not 
participated in the screening was 0.56 (95% Cl =  0.28-1.13). 
The rate ratio was 0.45 in the women aged 65-74 years at the 
most recent invitation (95% Cl =  0.20-1.02), whereas it was 
1.05 in the women aged 75 years and older (95% Cl =  0.27— 
4.14). While the breast cancer survival rate of the non-partici­
pant patients was fairly equal to that of patients from a control 
population, the underlying incidence rate of breast cancer was 
higher in the participants than in the non-participants. There­
fore, we conclude that bias was present, but that it had 
decreased our effect estimate. The real reduction in breast 
cancer mortality due to regular screening will be even larger. 
Regular mammographie screening of women over age 65 (at 
least up to 75 years) can reduce breast cancer mortality by 
approximately 45%.
© 1996 Wiley-Liss, Inc.
In women, the life-time risk of developing breast cancer has 
been estimated at 8.4-9.4% (Schouten et al, 1994). For women 
aged 65-69 years the probability of developing breast cancer 
before the age of 85 years is 1 in 16 and for those aged 70-74 
years 1 in 20 (Campbell et al, 1994). Thus, even in the very 
elderly, many cases of breast cancer are diagnosed. The 
proportion of patients who die from this disease is as large as it 
is in younger women (Beex and Wobbes, 1986). In patients 
aged 65-84 years, 5-year relative survival rates vary from about 
90% for those with localized disease to 66-69% for those with 
regional disease and to 17-20% for those with distant disease 
(Yancik et al, 1989).
In the past few decades, several randomized and non­
randomized trials have been undertaken to evaluate the effect 
of mammographie screening on breast cancer mortality. Exten­
sive evaluations on the available evidence have led to the 
conclusion that a 30-40% reduction in breast cancer mortality 
can be achieved by periodic screening of women aged 50-65 or 
70 years (Peeters et al, 1990; Rutqvist et al, 1990; Hurley and 
Kaldor, 1992; Fletcher et al, 1993; Nyström et al, 1993; De 
Koning et al, 1995). In women over the age of 70 years, 
evidence for a possible reduction in breast cancer mortality 
due to screening is lacking, because most trials did not include 
elderly women (Fletcher et al, 1993; Morrison, 1992).
In the late eighties and the early nineties, national screening 
programmes were initiated in several European countries, 
such as the United Kingdom, The Netherlands and Sweden 
(Shapiro, 1992). The lack of data showing that screening was of 
benefit to elderly women was the principal argument for not 
inviting women aged 65 years and more to screening programs 
in the UK (Woodman et al, 1995) and for excluding women
aged 70 years and older from programs in The Netherlands 
(NETB, 1995). Nevertheless, the question still remains as to 
whether continuing to screen women after they have reached 
these upper age limits will further reduce breast cancer 
mortality. With 18 years of follow-up data available in our 
Nijmegen screening program from the first screening round-up 
to December 31, 1993, we elected to conduct a case-control 
study on the effect of long-term participation after the age of 
65 years on breast cancer mortality.
STUDY POPULATION AND METHODS
Study setting
In the city of Nijmegen, population-based screening for 
breast cancer has been ongoing since 1975. Biennially, nearly 
30,000 women aged 40 years and older are personally invited to 
have a one-view mammogram. From round 2 (1977-1978) 
onwards, about 10,000 women aged 65 years and older have 
also been invited to participate. At each screening round, 
individual data on invitation and participation are stored in a 
computer file. Another file is kept on all Nijmegen breast 
cancer patients diagnosed within and outside the screening 
program. The follow-up of the population is registered with 
the help of the local authorities, who provide weekly lists of 
deceased women and those who have moved out of Nijmegen. 
Details of the program have been reported previously (Peer et 
al, 1994; Otten et al., 1996, in press).
Study desigfi and population
Within the Nijmegen population of invited women, we 
conducted a case-control study to investigate the effect of 
regular participation in the screening program from age 65 
years onwards on breast cancer mortality. The study popula­
tion consisted of women who 1) had been invited to participate 
at the age of 65 years or older and 2) had been free of breast 
cancer at the first screening invitation at age 65 years or older.
The cases were the patients who had died of breast cancer 
before January 1, 1994, The cause of death was classified by a 
panel of physicians who were unaware of the screening histoiy 
of the patients and was based on the clinical course of the 
disease and information about serious co-morbidity. Breast 
cancer was defined as the cause of death if the disease had 
progressed to distant sites and this progression was ultimately 
responsible for the death of the patient, or if in the presence of 
advanced disease other causes of death could be excluded. 
Patients with advanced breast cancer who died of other, 
unrelated causes were not included as cases. The study 
population comprised 82 cases. The screening round in which 
the case had received the most recent invitation just before the 
diagnosis of primary breast cancer was defined as the index
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round. For screen-detected cases the round in which the 
cancer had been detected was the index round.
For each case, a group of eligible population controls were 
selected who 1) were alive and residing in Nijmegen at the time 
of death of the case, 2) had been invited to participate in the 
index round of the case, 3) were free of breast cancer at their 
index invitation, and 4) were of the same age as the case at the 
index invitation. At random, 5 controls were selected for each 
case. Thus» the total number of controls was 410.
Definition of contrasted screening his to ties
A  history of no screening was defined as no participation in 
the 5 most recent screening rounds up to and including the 
index round. Women in this category represented the refer­
ence category.
A history of regular screening was defined as participation in 
the index round and having had a negative screening examina­
tion 1 round (approximately 2 years) earlier.
Histories that did not meet the criteria for “no screening” or 
“regular screening” were classified as otheiwise and formed a 
category in which we took no interest.
Cases and controls were classified according to these catego­
ries of screening histories.
Statistical analysis
We calculated the odds ratio with its 95% confidence inter­
val (95% Cl) as an estimator of the ratio of breast cancer mor­
tality rates (RR) in women with a histoiy of regular screening 
versus those with a history of no screening (Miettinen, 1976). 
Owing to the matched design, we used conditional logistic 
regression analysis with the software package EGRET.
RESULTS
Age at the index invitation was identical for cases and their 
matched controls (range, 65-92 years). At the index invitation, 
33% of the study population were 65-69 years old, 24% were 
70-74 years, 32% were 75-79 years and 11% were 80 years or 
older. The number of invitations was virtually the same for the 
cases and controls. Up to and including the index round, 23% 
of the cases and 21% of the controls had been invited only 
once, and 35% and 41% had been invited 2-4 times, respec­
tively, whereas 41% and 39% had been invited 5-8 times, 
respectively.
Table I shows the results of the conditional logistic regres­
sion analysis. The ratio of the breast cancer mortality rates (RR) 
of regularly screened women vs. unscreened women was 0.56 
(95% Cl = 0.28-1.13). In women aged 65-74 years at the index 
invitation the RR was 0.45 (95% Cl = 0.20-1.02); in women 
aged 75 and older, the RR was 1.05 (95% Cl = 0.27-4.14).
TABLE I -  BREAST CANCER MORTALITY RATH RATIO FOR SCREENING
HISTORY ACCORDING TO AGE AT INDEX INVITATION
Age at index 
invitation (years) Screening history
Number 
of cases/ 
controls
Breast cancer 
mortality rate 
ratio (95% Cl)
All ages No screening1 40/166 1
(65-92) Regular screening2 15/101. 0.56 (0.28-1.13)
Otherwise3 27/143 0.77 (0.44-1.34)
65-74 No screening 20/69
N jr 
1
Regular screening 12/87 0.45 (0.20-1.02)
Otherwise 15/79 0.64 (0.30-1.38)
75 and older No screening 20/97 1
Regular screening 3/14 1.05 (0.27-4.14)
Otherwise 12/64 0.90 (0.40-2.02)
*No participation in index round and 4 preceding rounds-Par­
ticipation in index round and negative mammogram in preceding 
round.-3Not meeting the criteria for ‘ ‘unscreened” or “screened”.
All over the world, the age-specific incidence of breast 
cancer is rising, especially among elderly women (Harris et al., 
1992). At the time of diagnosis, elderly patients are more likely 
to have distant métastasés or unknown stage disease than 
younger women (Yancik et a i , 1989; Bergman et ai, 1992). In 
the Nijmegen group of non-participants aged 70 years and 
older, 85% had stage II or stage Il-h cancer, in contrast to 77% 
of those aged 50-69 years. Among the regular participants, 
these percentages were 33% and 30%, respectively (Peer et al., 
1994).
After menopause, a large proportion of the fibroglandular 
breast tissue is replaced by fatty tissue, with greater radiologi- 
cal transparency (Costanza et al, 1992), thereby facilitating the 
detection of breast cancer by mammography. In addition, the 
proportion of false-positive screening results will be lower 
because of the decreased frequency of benign breast disease. 
The growth rate of breast cancer is relatively low in elderly 
women. Peer et al (1993) estimated that the median tumor 
volume doubling time is 80 days in patients younger than 50 
years, 157 days in patients aged 50-70 years and 188 days in 
older patients. The lower growth rate is in concordance with 
the higher rate of steroid-positive tumors (Clark et al, 1984). 
Life expectancy is relatively long, about 14 years at age 70 and 
about 8.5 years at age 80 years (Wegman, 1993). For the 
reasons given above, an important reduction in breast cancer 
mortality can also be expected in elderly women due to 
mammographie screening.
The few studies on the effect of breast cancer screening in 
women aged 65 years and older are small and have methodologi­
cal flaws. For instance, age-specific analyses involve age at 
entiy to the screening program instead of age at screening, and 
the comparisons are made between the “invited group” and 
the “control group” or between women “screened once” and 
those “never screened” (Verbeek et al, 1984, 1985; Morrison 
et ai, 1988; Brown and Flulka, 1988; Tabár et al, 1995; Chen et 
al, 1995). The most recent results from the Swedish 2-county 
trial for women aged 70-74 years at their first invitation for 
screening showed for the invited women a relative risk of 0.79 
for death from breast cancer (95% Cl = 0.51-1.22), compared 
with the non-invited women (Tabár et. al, 1995). Analysis of 
the women aged 65-74 years at their first invitation revealed 
RR = 0.68 (95% Cl = 0.51-0.89) (Chen et al, 1995). In the 
Nijmegen program, a case-control study was conducted on 
women who had been invited at least twice (Van Dijck et ai, 
1994). In this study, 33 cases and 165 controls aged 65 years 
and over at the index invitation were included, For women who 
had participated in the index screening, compared with those 
who had not participated, the RR was 0.58 (0.24-1.41). For 
women aged 65-74 years at the index invitation, the RR was 
0.34 (95% Cl = 0.12-0.97), whereas in the older women, an 
excess of mortality was found that could be attributed to 
self-selection bias (Van Dijck et al, 1994). In the present study, 
with 5 more years of follow-up and twice as many patients, the 
RR for women screened regularly compared with those not 
screened was 0.56 (95% Cl = 0.28-1.13); for women aged 
65-74, the RRwas 0.45 (95% Cl = 0.20-1.02); and for women 
aged 75 or over, the RR was 1.05 (95% Cl = 0.27-4.14). The 
agreement in the results, in spite of the difference in the 
definition of the relevant screening histories (participation in 
the index round for the former study and participation in both 
the index round and one round earlier in the present study), is 
noteworthy.
Screening can only improve the prognosis of breast cancer if 
it can detect more breast cancer cases in a curable phase than 
can be diagnosed without screening. Maximum benefit can 
only be expected if a woman participates on a regular basis. In 
our study, the definition of a regular screening history applied
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Time (years) since the diagnosis of breast cancer
F i g u r e  1 -  Breast cancer survival in Nijmegen non-participants 
and Arnhem patients. Note: patients diagnosed between 1977— 
1987 at the age of 65 years or older.
to women who continued to participate up to and including the 
index round and had had a negative screening mammogram 
approximately 2 years earlier. This definition guaranteed that 
in regularly screened patients, breast cancer had been diag­
nosed as early as possible in the given screening program. 
Screening mammograms performed 2 or more rounds before 
the index invitation were not expected to have any influence on 
the diagnosis of breast cancer and were therefore not taken 
into consideration. The reference category with a histoiy of no 
screening was also designed explicitly. After a negative screen­
ing result, a woman’s risk of developing breast cancer is low 
initially, but it approaches that of unscreened women after 
several years. After about 10 years, preceding screening can be 
expected to have lost its effect. We therefore defined a history 
of no screening as being present if a woman had never 
participated at all, or if she had rejected the index invitation 
and the 4 preceding ones. With this carefully designed con­
trast, we estimated that in women aged 65 years and older the 
reduction in breast cancer mortality for regularly screened 
women relative to the unscreened women was 44%.
Non-randomized studies are liable to self-selection bias that 
may (in part) explain the breast cancer mortality rate ratio 
observed in the screened vs. the unscreened group. Besides 
age, which was controlled for by matching, we only reviewed 
the information on previous referral for diagnostic work-up. 
Only 3 controls and no cases had been referred previously, so 
this cannot have caused any bias. However, there may have 
been a difference in the underlying breast cancer mortality
Overall survival
Time (years) since invitation at age 65-66 yrs
F igure  2 -  Overall survival o f  women screened at age  63-64 
years and invited at age 65-66 years .
between the screened and unscreened groups that had biased 
our results. To gain an insight into the direction of the bias, we 
first calculated the survival rate (Kaplan-Meier method) from 
diagnosis to death from breast cancer for the Nijmegen 
non-participant patients and compared it with that of Arnhem 
patients. Arnhem is a neighboring city with a similar popula­
tion size as in Nijmegen, where population screening for breast 
cancer was started in 1989. The cause of death of the Arnhem 
patients was determined in the same way as in Nijmegen. We 
selected patients aged 65 years or older at diagnosis who were 
diagnosed in 1977-1989. Figure 1 shows that the curve for the 
99 Nijmegen non-participants was fairly similar to that of the 
372 Arnhem patients.
Next, we compared the incidence rate of breast cancer in 
Nijmegen with that in Arnhem. In the period from January 1, 
1979 (after the Nijmegen population had undergone its first 
round of screening) to December 31, 1988, the incidence rate 
of breast cancer in Nijmegen equalled that in Arnhem (RR =  
0.97; 95% Cl = 0.83-1.14). We used log-linear modeling with 
the computer package GLIM and adjusted for age in 5-year 
categories: 65-69,70-74,75-79, 80-84 and 85 + . Subsequently, 
the Nijmegen population was restricted to non-participants. 
For the Nijmegen non-participants compared with the Arn­
hem population, the RR was 0.72 (95% Cl = 0.56-0.93). In the 
participants, the incidence of breast cancer must have been 
much higher than in the non-participants. Therefore, we 
conclude that the bias had reduced the estimated mortality 
reduction; the real effect must have been larger.
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In a study on the survival of breast cancer patients, Satari- 
ano and Ragland (1994) found that women with severe 
co-morbid conditions did not have a survival advantage be­
cause of early diagnosis. Death from other causes than breast 
cancer was the reason for this observation. We studied the 
overall survival rate from the date of invitation to round 3 
(1979-1980) in women aged 65-66 years at this invitation, who 
had participated in round 2 (Kaplan-Meier method). Figure 2 
shows that the women who participated in round 3 (n = 720) 
had a far higher survival rate than those who did not (n = 198).
Obviously, the participants had fewer co-morbid diseases or 
they were less severe. This means that the participants were at 
risk of dying from breast cancer for a longer period. Moreover, 
we conclude that the women who chose to continue to 
participate in the screening are those who may benefit from a 
survival advantage because of early diagnosis.
Classification of the cause of death of deceased breast 
cancer patients is difficult. Especially in elderly women, some 
degree of misclassification is unavoidable because of the 
presence of co-morbid conditions, including other malignan­
cies. In many patients, the origin of newly diagnosed métasta­
sés was not confirmed histologically. Autopsy had been per­
formed in 11% of the deceased patients only. This means that 
a new malignancy, for example of the lung, may have been 
misdiagnosed as a metastasis originating from the breast 
cancer (Lindgren, 1993). To avoid different misclassification 
for screened and unscreened patients, the classification proce­
dure was blinded for screening history. Misclassification that 
occurs independently of the screening history may have re­
duced the estimated mortality reduction.
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CONCLUSIONS
We conclude that continuing breast cancer screening after 
the age of 65 years, at least up to 75 years, will lead to a 
reduction in breast cancer mortality in elderly women. No 
effect of screening after 75 years was found, but only 8% of 
these women had participated regularly. However, the extent 
of harmful side effects of breast cancer screening increases 
with increasing age. Because the overall death rate is higher, 
some screen-detected patients may even die before the tumor 
would have become detectable clinically. The magnitude of 
both the effects and the side effects of continued mammo­
graphie screening after 65 years of age need to be evaluated. 
As a reduction in breast cancer mortality of 45% can be 
achieved in women over age 65 years, it seems unfair to 
exclude these women from national screening programs. A 
policy of screening elderly women free of charge if they request 
it, as is the case in the United Kingdom, seems preferable to 
excluding them totally.
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